First China-Made Rapid-Acting Insulin Wins US FDA ApprovalYicai·Jul 28 at 05:28 AM600867+0.36%603707-0.61%
NKF released its performance for the first three quarters, with a net profit attributable to the parent company of 429 million yuan, a year-on-year decrease of 29.11%Zhitong·Oct 24, 2025 at 11:13 AM603707-0.61%
NKF: Subsidiary Meitheal Pharmaceuticals Inc. received new drug injection registration approval from the U.S. FDA for phosphomycinZhitong·Oct 24, 2025 at 03:53 AM603707-0.61%
NKF: Products exported to the U.S. are generic drugs, and the impact of tariffs needs further observationZhitong·Sep 25, 2025 at 08:46 PM603707-0.61%
NKF released its semi-annual performance report, with a net profit attributable to the parent company of 286 million yuan, a year-on-year decrease of 29.32%Zhitong·Aug 28, 2025 at 08:51 AM603707-0.61%
NKF's subsidiary has obtained the US FDA's registration approval for the transfer of the production site of Etoposide InjectionZhitong·Jul 22, 2025 at 03:29 AM603707-0.61%
NKF's subsidiary has obtained the production site transfer registration approval for Dexamethasone Injection from the U.S. FDAZhitong·Jun 9, 2025 at 04:46 AM603707-0.61%
NKF's subsidiary product Hydrazine Hydrate Injection has been approved by the U.S. FDAZhitong·Jun 4, 2025 at 02:58 AM603707-0.61%
The concept of innovative drugs has strengthened again, with Staidson BioPharm rising over 15%, reaching a three-year highZhitong·May 28, 2025 at 08:42 PM603707-0.61%688336+3.61%
Huafu Securities: Maintains "Buy" rating on NKF, short-term fluctuations in Q1 2025 do not change long-term growth characteristicsZhitong·May 27, 2025 at 04:19 AM603707-0.61%
NKF: Plans to repurchase company shares for 20 million to 40 million yuan, with a repurchase price not exceeding 18.75 yuan per shareZhitong·May 26, 2025 at 03:40 AM603707-0.61%
The relevant announcements of listed companies expose the trend of long-term capital accumulationWallstreetcn·May 21, 2025 at 05:28 PM603707-0.61%002128-0.44%
Institutions are optimistic about these stocks todayZhitong·May 21, 2025 at 08:43 AM000538+0.21%688472-1.04%
NKF's subsidiary has obtained the production site transfer registration approval for Idarubicin Hydrochloride Injection from the U.S. FDAZhitong·May 19, 2025 at 04:47 AM603707-0.61%
NKF: In 2024, the net profit is expected to be 826 million yuan, a year-on-year increase of 536.09%Zhitong·Apr 28, 2025 at 07:14 AM603707-0.61%
